Citations as recorded by:

1. Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice

Diseases, 2017, 5(1) p. 5

DOI: 10.3390/diseases5010005

Citations as recorded by: Cross Ref PMC Google

2. Treatment of brain disease in the mucopolysaccharidoses

Molecular Genetics and Metabolism,

DOI: 10.1016/j.ymgme.2017.10.007

Citations as recorded by: Cross Ref

3. мукополисахаридозы: патогенез и будущее терапевтических подходов

Year: 2017

Citations as recorded by: Google

4. Small Molecules

Journal of Inborn Errors of Metabolism and Screening, 2016, 4 p. 232640981666629

DOI: 10.1177/2326409816666297

Citations as recorded by: Cross Ref

5. Emerging drugs for the treatment of mucopolysaccharidoses

Expert Opinion on Emerging Drugs, 2016, 21(1) p. 9

DOI: 10.1517/14728214.2016.1123690

Citations as recorded by: Cross Ref Google

6. N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice

Molecular Genetics and Metabolism, 2016, 118(2) p. 100

DOI: 10.1016/j.ymgme.2016.04.002

Citations as recorded by: Cross Ref Google

7. Activity of daily living for Morquio A syndrome

Molecular Genetics and Metabolism, 2016, 118(2) p. 111

DOI: 10.1016/j.ymgme.2016.04.005

Citations as recorded by: Cross Ref PMC Google

8. Small Molecules: Substrate Inhibitors, Chaperones, Stop-Codon Read Through, and Beyond

Year: 2016

Citations as recorded by: Google

9. Therapy for Lysosomal Storage Disorders: How Therapies are being Developed for Orphan Diseases

Year: 2016

Citations as recorded by: Google

10. Prospective therapies for mucopolysaccharidoses

Expert Opinion on Orphan Drugs, 2015, 3(11) p. 1241

DOI: 10.1517/21678707.2015.1089167

Citations as recorded by: Cross Ref Google

11. Molecular Therapy and Gene Therapy for Hurler Syndrome

Year: 2015

Citations as recorded by: Google

12. Нейронопатические мукополисахаридозы: патогенез и будущее терапевтических подходов

Year: 2015

Citations as recorded by: Google

13. Синдром Санфилиппо

Year: 2015

Citations as recorded by: Google

14. Current and potential therapeutic strategies for mucopolysaccharidoses

J Clin Pharm Ther, 2014, 39(3) p. 215

DOI: 10.1111/jcpt.12136

Citations as recorded by: Cross Ref Google

15. Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models

J Inherit Metab Dis, 2014, 37(5) p. 813

DOI: 10.1007/s10545-014-9703-x

Citations as recorded by: Cross Ref Google

16. Natural history of Sanfilippo syndrome type A

J Inherit Metab Dis, 2014, 37(3) p. 431

DOI: 10.1007/s10545-013-9661-8

Citations as recorded by: Cross Ref Google

17. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector

Gene Ther, 2014, 21(12) p. 1001

DOI: 10.1038/gt.2014.75

Citations as recorded by: Cross Ref Google

18. In vitro effect of genistein on DNA damage in leukocytes from mucopolysaccharidosis IVA patients

Molecular Genetics and Metabolism, 2014, 111(2) p. 205

DOI: 10.1016/j.ymgme.2013.11.011

Citations as recorded by: Cross Ref Google

19. Genistein ameliorates parathyroid hormone-induced epithelial-to-mesenchymal transition and inhibits expression of connective tissue growth factor in human renal proximal tubular cells

Arch Med Sci, 2013, 9 p. 724

DOI: 10.5114/aoms.2013.36929

Citations as recorded by: PMC

20. New strategies for the treatment of lysosomal storage diseases (review).

Int. J. Mol. Med., 2013, 31 p. 1

DOI: 1

Citations as recorded by: Google

21. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation

Osteoarthritis and Cartilage, 2013, 21(12) p. 1813

DOI: 10.1016/j.joca.2013.08.001

Citations as recorded by: Cross Ref Google

22. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder

Acta Paediatr, 2013, 102(5) p. 462

DOI: 10.1111/apa.12169

Citations as recorded by: Cross Ref PMC

23. Emerging therapies and therapeutic concepts for lysosomal storage diseases

Expert Opinion on Orphan Drugs, 2013, 1(5) p. 385

DOI: 10.1517/21678707.2013.780970

Citations as recorded by: Cross Ref Google

24. Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome)

Expert Opinion on Orphan Drugs,

DOI: 10.1517/21678707.2013.830069

Citations as recorded by: Cross Ref Google

25. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism …

Year: 2013

Citations as recorded by: Google

26. Leukodystrophies and Lysosomal Storage Disorders

Year: 2013

Citations as recorded by: Google

27. Gene expression-targeted isoflavone therapy

IUBMB Life, 2012, 64(4) p. 307

DOI: 10.1002/iub.1007

Citations as recorded by: Cross Ref

28. Putative Biological Mechanisms of Efficiency of Substrate Reduction Therapies for Mucopolysaccharidoses

Arch. Immunol. Ther. Exp., 2012, 60(6) p. 461

DOI: 10.1007/s00005-012-0195-9

Citations as recorded by: Cross Ref Google

29. Quantitative estimation of lysosomal storage in mucopolysaccharidoses by electron microscopy analysis.

Acta Biochim. Pol., 2012, 59 p. 6

Citations as recorded by: Google

30. Nutraceutical-mediated restoration of wild-type levels of IKBKAP-encoded IKAP protein in familial dysautonomia-derived cells

Mol. Nutr. Food Res., 2012, 56(4) p. 570

DOI: 10.1002/mnfr.201100670

Citations as recorded by: Cross Ref

31. Changes in hair morphology as a biomarker in gene expression-targeted isoflavone therapy for Sanfilippo disease

Gene, 2012, 504(2) p. 292

DOI: 10.1016/j.gene.2012.05.006

Citations as recorded by: Cross Ref Google

32. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse

Molecular Genetics and Metabolism, 2012, 105(1) p. 116

DOI: 10.1016/j.ymgme.2011.10.005

Citations as recorded by: Cross Ref PMC

33. Synthetic genistein derivatives as modulators of glycosaminoglycan storage

J Transl Med, 2012, 10 p. 153

DOI: 10.1186/1479-5876-10-153

Citations as recorded by: PMC Google

34. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS IH in the Idua-W392X mouse

Year: 2012

Citations as recorded by: Google

35. Innovative therapeutic approaches for improving patient life condition with a neurological lysosomal disease

Year: 2012

Citations as recorded by: Google

36. Cardiac Involvement in the Mucopolysaccharide Disorders

Year: 2012

Citations as recorded by: Google

37. Nuovi approcci terapeutici alle malattie da accumulo lisosomiale

Year: 2012

Citations as recorded by: Google

38. The Use of Elevated Doses of Genistein-Rich Soy Extract in the Gene Expression-Targeted Isoflavone Therapy for Sanfilippo Disease Patients

JIMD Rep, 2011, 5 p. 21

DOI: 10.1007/8904_2011_87

Citations as recorded by: PMC Google

39. Lysosomale Speicherkrankheiten

Monatsschr Kinderheilkd, 2011, 159(9) p. 821

DOI: 10.1007/s00112-011-2445-z

Citations as recorded by: Cross Ref

40. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT)

Am. J. Med. Genet., 2011, 155(9) p. 2257

DOI: 10.1002/ajmg.a.34146

Citations as recorded by: Cross Ref

41. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression‐targeted isoflavone therapy (GET …

Year: 2011

Citations as recorded by: Google